Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LISATA THERAPEUTICS, INC.CLBS · Entity 7814 | Director | January 10, 2022 | January 12, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LISATA THERAPEUTICS, INC.
Report date January 10, 2022 · Filed January 12, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 212,269 |
Reported balance
After 2022-01-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-01-10 · Grant · Acquired 65,430 · Balance 212,269 F1: Represents 65,430 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 10, 2023. F2: Includes 103,165 unvested restricted stock units. |
| Common StockSEC Table I · non-derivative | IndirectBy Steven S Myers IRA | 8,434 |
Reported balance
Holding disclosure · report date 2022-01-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 8,434 |
| Common StockSEC Table I · non-derivative | IndirectBy Steven S Myers Revocable Trust dated 12/1/2000 | 1,954 |
Reported balance
Holding disclosure · report date 2022-01-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,954 |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 802 |
Reported balance
Holding disclosure · report date 2022-01-10 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 802 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 65,430 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 10, 2023.
F2: Includes 103,165 unvested restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 10, 2022 Filed Jan 12, 2022 21:13 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 65,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001078274-22-000002 · wf-form4_164202201016542.xml · nonDerivative · entry 1 MYERS STEVEN S · CIK 0001078274 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,269 F1 · shares: Represents 65,430 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 10, 2023. F2 · balance_after: Includes 103,165 unvested restricted stock units. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 22:03 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | PurchaseCommon Stock | 33,785 | $0.89 | $30,190.28 |
DisclosureSEC source: 0001078274-21-000006 · wf-form4_163917382551212.xml · nonDerivative · entry 1 MYERS STEVEN S · CIK 0001078274 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,839 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8802 to $0.9000, inclusive. The reporting person undertakes to provide Caladrius Biosciences, Inc., any security holder of Caladrius Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · balance_after: Represents 37,735 unvested restricted stock awards granted under Issuer's 2018 Equity Incentive Compensation plan, which will vest on January 11, 2022. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 23:19 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 37,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001078274-21-000003 · wf-form4_161049352547004.xml · nonDerivative · entry 1 MYERS STEVEN S · CIK 0001078274 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,054 F1 · shares: Represents 37,735 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 11, 2022. F2 · balance_after: Includes 56,027 unvested restricted stock units. Read SEC document |
| January 13, 2020 Filed Jan 14, 2020 21:16 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantRestricted Stock Units | 18,292 | $3.28 | $59,997.76 |
DisclosureSEC source: 0001078274-20-000002 · wf-form4_157903658241365.xml · nonDerivative · entry 1 MYERS STEVEN S · CIK 0001078274 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,319 F1 · shares: Represents 18,292 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 13, 2021. F2 · balance_after: Includes 18,292 unvested restricted stock units. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:07 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantRestricted Stock Units | 12,121 | $4.95 | $59,998.95 |
DisclosureSEC source: 0001078274-19-000009 · wf-form4_154767285392941.xml · nonDerivative · entry 1 MYERS STEVEN S · CIK 0001078274 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,027 F1 · shares: Represents 12,121 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 14, 2020. F2 · balance_after: Includes 12,121 unvested restricted stock units. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 17:24 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 8,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001078274-19-000006 · wf-form4_154714104137179.xml · nonDerivative · entry 1 MYERS STEVEN S · CIK 0001078274 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,906 F1 · shares: Represents 8,747 shares underlying restricted stock granted under the 2018 Equity Incentive Compensation Plan which were awarded on January 8, 2018 and which vested on January 8, 2019. Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 21:06 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantRestricted Stock Units · Derivative | 8,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-001701 · tv483051_4.xml · derivative · entry 1 MYERS STEVEN S · CIK 0001078274 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,747 Underlying: Common Stock · 8,747 shares Expires 2028-01-08 F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on the date that is one year from the date of grant. Read SEC document |
| May 16, 2017 Filed May 18, 2017 20:59 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 2,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-028452 · v467406_4.xml · nonDerivative · entry 1 MYERS STEVEN S · CIK 0001078274 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,159 F1 · shares: Represents an award of 2,565 Restricted Stock Units granted under the Issuer's 2015 Equity Compensation Plan that will vest on May 16, 2018. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. F2 · balance_after: Includes 750 shares of unvested restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on June 22, 2017, 1,650 shares of unvested restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on January 9, 2018, 2,565 shares of unvested Restricted Stock Units granted under the Issuer's 2015 Equity Compensation Plan that will vest on May 16, 2018 and 312 shares of unvested restricted stock granted under the Issuer's 2009 Equity Compensation Plan that will vest quarterly through June 2, 2018. Read SEC document |
| January 09, 2017 Filed Jan 31, 2017 23:51 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantOptions to Purchase Common Stock · Derivative | 2,750 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001144204-17-005183 · v458002_4.xml · derivative · entry 5 MYERS STEVEN S · CIK 0001078274 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Underlying: Common Stock · 2,750 shares Expires 2027-01-09 Read SEC document |
| January 09, 2017 Filed Jan 31, 2017 23:51 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 1,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-005183 · v458002_4.xml · nonDerivative · entry 1 MYERS STEVEN S · CIK 0001078274 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,594 F1 · shares: Represents 1,650 shares of restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on January 9, 2018. F2 · balance_after: Includes 2,775 shares of unvested restricted stock granted under the Issuer's compensation plans. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.